Open AccessSafety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer
Author(s) -
George Calcanes,
Jeffrey Vacirca
Publication year - 2019
Publication title -
journal of infusion nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.35
H-Index - 35
eISSN - 1539-0667
pISSN - 1533-1458
DOI - 10.1097/nan.0000000000000341
Subject(s) - medicine , nausea , vomiting , adverse effect , chemotherapy , cancer , safety profile , anesthesia , cancer chemotherapy
HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified.